Candidate gene mutation analysis in bilateral adrenal pheochromocytoma and sympathetic paraganglioma

Endocrine-Related Cancer

Volumn 14, Issue 2, 2007, Pages 453-462

  Korpershoek, Esther ^a   Petri, Bart Jeroen ^a   Van Nederveen, Francien H ^a   Dinjens, Winand N M ^a   Verhofstad, Albert A ^b   De Herder, Wouter W ^c   Schmid, Sonja ^d   Perren, Aurel ^d   Komminoth, Paul ^d   De Krijger, Ronald R ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN RET; PROTEIN SUBUNIT; SUCCINATE DEHYDROGENASE;

ADOLESCENT; ADRENAL MEDULLA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ALGORITHM; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NUCLEOTIDE SEQUENCE; PARAGANGLIOMA; PHEOCHROMOCYTOMA; SYMPATHETIC GANGLION; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; AMINO ACID SEQUENCE; ANIMALS; CATTLE; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, NEOPLASM; GERM-LINE MUTATION; HUMANS; IRON-SULFUR PROTEINS; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTO-ONCOGENE PROTEINS C-RET; RATS; SUCCINATE DEHYDROGENASE; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34547819216     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-06-0044     Document Type: Article

References (36)

1. Ackrell BA 2002 Cytopathies involving mitochondrial complex II. Molecular Aspects of Medicine 23 369-384.
2. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, Chabre O, Chamontin B, Delemer B, Giraud S, Murat A et al. 2005 Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology 23 8812-8818.
3. Baysal BE, Willett-Brozick JE, Lawrence EC, Drovdlic CM, Savul SA, McLeod DR, Yee HA, Brackmann DE, Slattery WH III, Myers EN et al. 2002 Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. Journal of Medical Genetics 39 178-183.
4. Benn DE, Gimenez-Roqueplo AP, Reilly JR, Bertherat J, Burgess J, Byth K, Croxson M, Dahia PL, Elston M, Gimm O et al. 2005 Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. Journal of Clinical Endocrinology and Metabolism 91 827-836.
5. Brouwers FM, Eisenhofer G, Tao JJ, Kant JA, Adams KT, Linehan WM & Pacak K 2006 High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. Journal of Clinical Endocrinology and Metabolism 91 4505-4509.
6. Bryant J, Farmer J, Kessler LJ, Townsend RR & Nathanson KL 2003 Pheochromocytoma: the expanding genetic differential diagnosis. Journal of the National Cancer Institute 95 1196-1204.
7. Cascon A, Ruiz-Llorente S, Cebrian A, Leton R, Telleria D, Benitez J & Robledo M 2003 G12S and H50R variations are polymorphisms in the SDHD gene. Genes, Chromosomes and Cancer 37 220-221.
8. Cascon A, Ruiz-Llorente S, Fraga MF, Leton R, Telleria D, Sastre J, Diez JJ, Martinez Diaz-Guerra G, Diaz Perez JA, Benitez J et al. 2004 Genetic and epigenetic profile of sporadic pheochromocytomas. Journal of Medical Genetics 41 e30.
9. Cascon A, Montero-Conde C, Ruiz-Llorente S, Mercadillo F, Leton R, Rodriguez-Antona C, Martinez-Delgado B, Delgado M, Diez A, Rovira A et al. 2005 Gross SDHB deletions in patients with paraganglioma detected by multiplex PCR: a possible hot spot? Genes, Chromosomes and Cancer 45 213-219.
10. Dannenberg H, De Krijger RR, van der Harst E, Abbou M, Y IJ, Komminoth P & Dinjens WN 2003 Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas. International Journal of Cancer 105 190-195.
11. Dannenberg H, van Nederveen FH, Abbou M, Verhofstad AA, Komminoth P, de Krijger RR & Dinjens WN 2005 Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. Journal of Clinical Oncology 23 1894-1901.
12. Eng C 1996 Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. New England Journal of Medicine 335 943-951.
13. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF & Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research 63 5615-5621.
14. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, Neumann H, Opocher G, Maher ER & Plouin PF 2006 Phaeochromocytoma, new genes and screening strategies. Clinical Endocrinology 65 699-705.
15. Gimm O 2005 Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. Familial Cancer 4 17-23.
16. van der Harst E, de Krijger RR, Dinjens WN, Weeks LE, Bonjer HJ, Bruining HA, Lamberts SW & Koper JW 1998a Germline mutations in the vhl gene in patients presenting with phaeochromocytomas. International Journal of Cancer 77 337-340.
17. van der Harst E, de Krijger RR, Bruining HA, Lamberts SW, Bonjer HJ, Dinjes WN, Proye C, Koper JW, Bosman FT, Roth J et al. 1998b Prognostic value of RET proto-oncogene point mutations in malignant and benign, sporadic phaeochromocytomas. International Journal of Cancer 79 537-540.
18. Komminoth P, Kunz E, Hiort O, Schroder S, Matias-Guiu X, Christiansen G, Roth J & Heitz PU 1994 Detection of RET proto-oncogene point mutations in paraffin-embedded pheochromocytoma specimens by nonradioactive single-strand conformation polymorphism analysis and direct sequencing. American Journal of Pathology 145 922-929.
19. Lenders JW, Eisenhofer G, Mannelli M & Pacak K 2005 Phaeochromocytoma. Lancet 366 665-675.
20. Machens A, Gimm O, Hinze R, Hoppner W, Boehm BO & Dralle H 2001 Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. Journal of Clinical Endocrinology and Metabolism 86 1104-1109.
21. Machens A, Brauckhoff M, Holzhausen HJ, Thanh PN, Lehnert H & Dralle H 2005 Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2. Journal of Clinical Endocrinology and Metabolism 90 3999-4003.
22. Maier-Woelfle M, Brandle M, Komminoth P, Saremaslani P, Schmid S, Locher T, Heitz PU, Krull I, Galeazzi RL, Schmid C et al. 2004 A novel succinate dehydrogenase subunit B gene mutation, H132P, causes familial malignant sympathetic extraadrenal paragangliomas. Journal of Clinical Endocrinology and Metabolism 89 362-367.
23. Maranchie JK, Afonso A, Albert PS, Kalyandrug S, Phillips JL, Zhou S, Peterson J, Ghadimi BM, Hurley K, Riss J et al. 2004 Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Human Mutation 23 40-46.
24. McWhinney SR, Pilarski RT, Forrester SR, Schneider MC, Sarquis MM, Dias EP & Eng C 2004 Large germline deletions of mitochondrial complex II subunits SDHB and SDHD in hereditary paraganglioma. Journal of Clinical Endocrinology and Metabolism 89 5694-5699.
25. Montani M, Schmitt AM, Schmid S, Locher T, Saremaslani P, Heitz PU, Komminoth P & Perren A 2005 No mutations but an increased frequency of SDHx polymorphisms in patients with sporadic and familial medullary thyroid carcinoma. Endocrine-Related Cancer 12 1011-1016.
26. van Nederveen FH, Korpershoek E, Lenders JW, de Krijger RR & Dinjens WNM 2007 Somatic SDHB mutation in an extra-adrenal pheochromocytoma. New England Journal of Medicine (in press).
27. Neumann HP, Hoegerle S, Manz T, Brenner K & Iliopoulos O 2002 How many pathways to pheochromocytoma? Seminars in Nephrology 22 89-99.
28. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M, Buchta M, Franke G, Klisch J, Bley TA et al. 2004 Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 943-951.
29. Peczkowska M & Januszewicz A 2005 Multiple endocrine neoplasia type 2. Familial Cancer 4 25-36.
30. Perren A, Barghorn A, Schmid S, Saremaslani P, Roth J, Heitz PU & Komminoth P 2002 Absence of somatic SDHD mutations in sporadic neuroendocrine tumors and detection of two germline variants in paraganglioma patients. Oncogene 21 7605-7608.
31. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ et al. 2005 Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Human Molecular Genetics 14 2231-2239.
32. Roman S 2004 Pheochromocytoma and functional paraganglioma. Current Opinion in Oncology 16 8-12.
33. Schiavi F, Boedeker CC, Bausch B, Peczkowska M, Gomez CF, Strassburg T, Pawlu C, Buchta M, Salzmann M, Hoffmann MM et al. 2005 Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 294 2057-2063.
34. Taschner PE, Jansen JC, Baysal BE, Bosch A, Rosenberg EH, Brocker-Vriends AH, van Der Mey AG, van Ommen GJ, Cornelisse CJ & Devilee P 2001 Nearly all hereditary paragangliomas in the Netherlands are caused by two founder mutations in the SDHD gene. Genes, Chromosomes and Cancer 31 274-281.
35. Thakker RV 2001 Multiple endocrine neoplasia. Hormone Research 56 67-72.
36. Young AL, Baysal BE, Deb A & Young WF Jr 2002 Familial malignant catecholamine-secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. Journal of Clinical Endocrinology and Metabolism 87 4101-4105.